Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

Ronald A. Fleming, Robert L. Capizzi, Gary L. Rosner, Lawrence K. Oliver, Stephen J. Smith, Charles A. Schiffer, Richard T. Silver, Bruce A Peterson, Raymond B. Weiss, George A. Omura, Robert J. Mayer, David A. Van Echo, Clara D. Bloomfield, Richard L. Schilsky

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315, P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

Original languageEnglish (US)
Pages (from-to)425-430
Number of pages6
JournalCancer chemotherapy and pharmacology
Volume36
Issue number5
DOIs
StatePublished - Sep 1995

Keywords

  • Cytarabine
  • Leukemia

Fingerprint Dive into the research topics of 'Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study'. Together they form a unique fingerprint.

Cite this